These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1887797)

  • 21. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.
    Handley DA; Van Valen RG; Melden MK; Flury S; Lee ML; Saunders RN
    Immunopharmacology; 1986 Aug; 12(1):11-6. PubMed ID: 3019921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor.
    Norman JG; Sutton ET; Franz MS; Baker CH
    Shock; 1995 May; 3(5):369-75. PubMed ID: 7648339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo.
    Heuer HO; Letts G; Meade CJ
    J Lipid Mediat; 1990; 2 Suppl():S101-8. PubMed ID: 2133276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D; Merlos M; Giral M; Ferrando R; Garcia-Rafanell J; Forn J
    Drugs Exp Clin Res; 1997; 23(5-6):191-9. PubMed ID: 9515229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
    Wilson DV; Eberhart SW; Robinson NE; Rice R; Gray PR
    Am J Vet Res; 1993 Feb; 54(2):274-9. PubMed ID: 8430938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
    J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microvascular vasopressin effects during endotoxin shock in the rat.
    Baker CH; Sutton ET; Zhou Z; Dietz JR
    Circ Shock; 1990 Feb; 30(2):81-95. PubMed ID: 2178794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock.
    Yamanaka S; Iwao H; Yukimura T; Kim S; Miura K
    Br J Pharmacol; 1993 Dec; 110(4):1501-7. PubMed ID: 8306093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet activating factor (PAF) increases leukocyte adhesion but does not alter vessel diameter in the rat mesenteric microcirculation.
    Smalley DM; Wood JG; Childs EW; Frank LL; Cheung LY
    Microvasc Res; 1998 Nov; 56(3):271-6. PubMed ID: 9828165
    [No Abstract]   [Full Text] [Related]  

  • 31. The platelet-activating factor antagonist BB-882 does not improve tissue oxygen extraction in endotoxic shock.
    Spapen H; Zhang H; Verhaeghe V; Smail N; Vincent JL
    J Crit Care; 1998 Jun; 13(2):81-90. PubMed ID: 9627275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and regional hemodynamic changes during endotoxin or platelet activating factor (PAF)-induced shock in rats.
    Mulder MF; van Lambalgen AA; van Kraats AA; Scheffer PG; Bouman AA; van den Bos GC; Thijs LG
    Circ Shock; 1993 Dec; 41(4):221-9. PubMed ID: 8143350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of LTB4 receptor antagonists in endotoxic shock in the rat.
    Li EJ; Cook JA; Wise WC; Jackson WT; Halushka PV
    Circ Shock; 1991 Aug; 34(4):385-92. PubMed ID: 1663429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is platelet activating factor (PAF) a mediator of endotoxin shock?
    Terashita Z; Imura Y; Nishikawa K; Sumida S
    Eur J Pharmacol; 1985 Feb; 109(2):257-61. PubMed ID: 3996473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myoelectric intestinal disturbances in Escherichia coli endotoxic shock in rats. Involvement of platelet-activating factor.
    Pons L; Droy-Lefaix MT; Braquet P; Buéno L
    Lipids; 1991 Dec; 26(12):1359-61. PubMed ID: 1819734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of vasoconstriction by platelet activating factor in the in situ blood perfused rat mesentery.
    Gerkens JF
    Clin Exp Pharmacol Physiol; 1989 Mar; 16(3):161-7. PubMed ID: 2721028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental studies on the relation of platelet activating factor (PAF) to high mortality in sublethal endotoxemia after massive hepatectomy and effects of its antagonist].
    Onuki Y; Nakamura S; Muro H; Baba S
    Nihon Geka Gakkai Zasshi; 1993 May; 94(5):466-74. PubMed ID: 8332121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of platelet-activating factor antagonist SRI 63-441 on endotoxemia in sheep.
    Sessler CN; Glauser FL; Davis D; Fowler AA
    J Appl Physiol (1985); 1988 Dec; 65(6):2624-31. PubMed ID: 3145934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia.
    Carrick JB; Morris DD; Moore JN
    Equine Vet J; 1993 Mar; 25(2):152-7. PubMed ID: 8385601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.
    Fletcher JR; DiSimone AG; Earnest MA
    Ann Surg; 1990 Mar; 211(3):312-6. PubMed ID: 2178565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.